English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objectives  To present the baseline patient‐reported outcome measures ( PROM s) in the Prostate Testing for Cancer and Treatment (ProtecT) randomized trial comparing active monitoring, radical prostatectomy and external‐beam conformal radiotherapy for localized prostate cancer and to compare results with other populations.    Materials and Methods  A total of 1643 randomized men, aged 50–69 years and diagnosed with clinically localized disease identified by prostate‐specific antigen ( PSA ) testing, in nine  UK  cities in the period 1999–2009 were included. Validated  PROM s for disease‐specific (urinary, bowel and sexual function) and condition‐specific impact on quality of life (Expanded Prostate Index Composite [ EPIC ], 2005 onwards; International Consultation on Incontinence Questionnaire‐Urinary Incontinence [ ICIQ ‐ UI ], 2001 onwards; the International Continence Society short‐form male survey [ ICS male SF ]; anxiety and depression (Hospital Anxiety and Depression Scale [ HADS ]), generic mental and physical health (12‐item short‐form health survey [ SF ‐12]; EuroQol quality‐of‐life survey, the  EQ ‐5D‐3L) were assessed at prostate biopsy clinics before randomization. Descriptive statistics are presented by treatment allocation and by men's age at biopsy and  PSA  testing time points for selected measures.    Results  A total of 1438 participants completed biopsy questionnaires (88%) and 77–88% of these were analysed for individual  PROM s. Fewer than 1% of participants were using pads daily (5/754). Storage lower urinary tract symptoms were frequent (e.g. nocturia 22%, 312/1423). Bowel symptoms were rare, except for loose stools (16%, 118/754). One third of participants reported erectile dysfunction (241/735) and for 16% (118/731) this was a moderate or large problem. Depression was infrequent (80/1399, 6%) but 20% of participants (278/1403) reported anxiety. Sexual function and bother were markedly worse in older men (65–70 years), whilst urinary bother and physical health were somewhat worse than in younger men (49–54 years, all  P  < 0.001). Bowel health, urinary function and depression were unaltered by age, whilst mental health and anxiety were better in older men ( P  < 0.001). Only minor differences existed in mental or physical health, anxiety and depression between  PSA  testing and biopsy assessments.    Conclusion  The ProtecT trial baseline  PROM s response rates were high. Symptom frequencies and generic quality of life were similar to those observed in populations screened for prostate cancer and control subjects without cancer.

bju international

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life